Lilly Completes Acquisition of DICE Therapeutics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Eli Lilly & Co. (LLY) upgraded at Jefferies - sees near-term revenue and EPS upside
August 9, 2023 11:00 AM EDTEli Lilly & Co. (NYSE: LLY) was raised to Buy from Hold at Jefferies on Wednesday, with analyst Akash Tewari raising the price target to $615 per share from $430.
The upgrade follows two positive data points for the pharmaceutical company. Tewari explained that "SELECT showed... More
